Page 139 - Haematologica July

Efficacy of BR as first salvage treatment in CLL
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7):1602-1604.
4. Foà R, Guarini A. A mechanism-driven treatment for chronic lymphocytic leukemia? N Engl J Med. 2013;369(1):85-87.
5. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
6. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
7. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):311-322.
8. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratifica- tion, and treatment. Am J Hematol. 2017;92(9):946-965.
9. Buske C, Hutchings M, Ladetto M, et al. ESMO Consensus Conference on malig- nant lymphoma: general perspectives and recommendations for the clinical manage- ment of the elderly patient with malignant lymphoma. Ann Oncol. 2018;29(3):544- 562.
10. Wierda WG, Zelenetz AD, Gordon LI, et al. NCCN Guidelines Insights: chronic lym- phocytic leukemia/small lymphocytic leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017;15(3):293-311.
11. Green MR, Williams ME, Willey J, Buettner A, Neely D, Lankford M. First-Line Prescribing Preferences of U.S. Hematology-Oncology Physicians for Patients with CLL: Impact of Novel Agents [abstract]. Blood. 2014;124(21):4676.
12. Cramer P, Fink AM, Busch R, et al. Second- line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and ritux- imab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leuk Lymphoma. 2013;54(8):1821-1822.
13. Fornecker LM, Aurran-Schleinitz T, Michallet AS, et al. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. Am J Hematol. 2015;90(6):511-514.
14. Knauf W, Abenhardt W, Dörfel S, et al. Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms. Hematol Oncol. 2015;33(1):15- 22.
15.
16.
17.
18.
19.
20.
21.
22. 23.
24.
25.
Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicen- ter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559-3566. Cortelezzi A, Sciumè M, Liberati AM, et al. Bendamustine in combination with ofatu- mumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia. 2014;28(3):642-648.
Coutré SE, Furman RR, Flinn IW, et al. Extended treatment with single-agent Ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Cancer Res. 2017;23(5):1149-1155. O'Brien SM, Furman RR, Coutre SE, et al. Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood. 2016; 128:233.
Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high- risk prognostic factors from the phase 3 RESONATE study in patients with previ- ously treated CLL/SLL. Leukemia. 2018 32(1):83-91.
UK CLL Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of out- comes in 315 patients. Haematologica. 2016;101(12):1563-1572.
Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lym- phocytic leukemia: data from 95 consecu- tive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573-1580. Ghia P, Cuneo A. Ibrutinib in the real world patient: many lights and some shades. Haematologica. 2016;101(12):1448-1450. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456.
International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL- IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790. Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination
with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297-311.
26. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previous- ly treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211.
27. Follows GA and CLL Forum UK. Outcomes of patients post ibrutinib treatment for relapsed/refractory CLL: a UK and Ireland analysis [abstract]. Hematol Oncol. 2017;35:237-238.
28. Compagno M, Wang Q, Pighi C, et al. Phosphatidylinositol 3-kinase blockade increases genomic instability in B cells. Nature. 2017;542(7642):489-493.
29. Hillmen P, Fraser G, Jones J, et al. Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials. Blood. 2015;126(23):2944.
30. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
31. Salles GA, Baseggio L, Bachy E, et al. Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATETM and RES- ONATE-2TM with the French Lyon-Sud Database. Blood. 2016;128(22):2039.
32. Hansson L, Asklid A, Diels J, et al. Ibrutinib versus previous standard of care: an adjust- ed comparison in patients with relapsed/refractory chronic lymphocytic leukaemia. Ann Hematol. 2017; 96(10):1681-1691.
33. Mato AR, Lamanna N, Ujjani CS, et al. Toxicities and Outcomes of Ibrutinib- Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. Blood. 2016;128(22):3222.
34. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre- Planned Interim Analysis of the Randomized Phase 3 Murano Study [abstract]. Blood. 2017;130(Suppl 1):LBA-2.
haematologica | 2018; 103(7)
1217